Dr. Ron Schoner brought over 30 years of experience in biopharmaceutical development, specializing in therapeutic proteins and biologics. He led teams that advanced a broad range of products—from early recombinant proteins such as insulin and human growth hormone to monoclonal antibodies, fusion proteins, and bispecifics.
During his 25 years at Eli Lilly, Dr. Schoner helped pioneer recombinant DNA and E. coli-based expression technologies. Later, as Scientific Director at MedImmune, he contributed to bioprocess innovations supporting a rapidly growing biologics portfolio.
Dr. Schoner earned his Ph.D. from Purdue University and completed postdoctoral research at Johns Hopkins University School of Medicine. He has authored more than 20 scientific publications and patents.
